Saturna Capital Corp Has $193,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Saturna Capital Corp grew its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 7.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,553 shares of the biotechnology company’s stock after purchasing an additional 1,353 shares during the period. Saturna Capital Corp’s holdings in Iovance Biotherapeutics were worth $193,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of IOVA. Oppenheimer & Co. Inc. acquired a new stake in shares of Iovance Biotherapeutics during the first quarter worth approximately $246,000. Sei Investments Co. boosted its stake in shares of Iovance Biotherapeutics by 33.9% during the 1st quarter. Sei Investments Co. now owns 333,148 shares of the biotechnology company’s stock valued at $4,937,000 after buying an additional 84,382 shares during the period. US Bancorp DE grew its holdings in shares of Iovance Biotherapeutics by 113.8% during the 1st quarter. US Bancorp DE now owns 31,557 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 16,800 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Iovance Biotherapeutics by 14.5% in the first quarter. ProShare Advisors LLC now owns 62,210 shares of the biotechnology company’s stock worth $922,000 after acquiring an additional 7,891 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Iovance Biotherapeutics by 9.2% during the first quarter. Vanguard Group Inc. now owns 24,915,300 shares of the biotechnology company’s stock worth $369,245,000 after acquiring an additional 2,102,480 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Wednesday, November 6th. Piper Sandler lowered shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $19.00 to $10.00 in a research note on Monday, July 29th. StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a research note on Monday, August 12th. Finally, UBS Group assumed coverage on shares of Iovance Biotherapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $17.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.33.

Iovance Biotherapeutics Stock Down 7.1 %

Iovance Biotherapeutics stock opened at $9.00 on Thursday. The business has a 50 day moving average price of $10.12 and a two-hundred day moving average price of $9.78. Iovance Biotherapeutics, Inc. has a 12 month low of $4.29 and a 12 month high of $18.33. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of -6.04 and a beta of 0.60.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The company had revenue of $58.56 million during the quarter, compared to analysts’ expectations of $53.54 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. During the same quarter in the prior year, the company posted ($0.46) EPS. On average, analysts expect that Iovance Biotherapeutics, Inc. will post -1.25 earnings per share for the current fiscal year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.